Jan Biegus

739 posts

Jan Biegus banner
Jan Biegus

Jan Biegus

@JanBiegus

MD PhD, Cardiology, Heart Failure and Intensive Cardiac Care. Wroclaw Medical University, Poland. #ESC Heart Failure Deputy Editor-in-Chief

Wrocław, Polska Katılım Mayıs 2021
283 Takip Edilen456 Takipçiler
Jan Biegus retweetledi
Marta Cobo Marcos
Marta Cobo Marcos@MartaCoboMarcos·
📢Growing evidence of the usefulness/safety of a natriuresis/guided diuretic therapy in acute HF. Let´s use it!! @ICardiacaSEC @IcyfaSemi
Juan Carlos López-Azor@jclopezazor

Delighted to share the publication of the #EDICA study in @JCardFail doi.org/10.1016/j.card… In patients 🏥 with acute HF, a natriuresis/diuresis-guided decongestion strategy (@escardio guidelines) vs a weight-guided one showed: ✅ Greater 5-day NT-proBNP reduction 🟰 5-day clinical decongestion 🟰 Length of stay & 30-day outcomes (🏥/☠️) 🟰 Safety & feasibility 🔎 Trend toward not sustained ⬆️ 24–48 h diuresis, weight loss, & loop-diuretic dose Some conclussions: 1️⃣ Time matters: earlier identification of diuretic resistance improves biomarker decongestion 2️⃣ Yet this did not translate into better short-term clinical outcomes 🎯Still need to close the gap between decongestion and clinical outcomes: Timing of assessment? Faster titration? Earlier combination diuretic therapy? Thanks to the great collab of Cardiology - Internal Medicine - Emergency Dep @MartaCoboMarcos @JanBiegus @esthermonteroh @fernidom @DeCastro9 @dr_pavia @segoviajavierve @ICardiacaSEC @secardiologia @CardioRenalSEC @HospiPtaHierro @Sociedad_SEMI @IcyfaSemi @SEMES_

English
0
11
34
4.6K
Jan Biegus retweetledi
Ahmed Bennis MD 🫀
Ahmed Bennis MD 🫀@drbennisahmed·
Contemporary heart failure evidence in 2025: a joint summary of key trials from the European Journal of Heart Failure and ESC Heart Failure Journal Despite an expanding therapeutic armamentarium, delayed diagnosis, underuse of evidence-based therapies, and organizational barriers continue to limit clinical impact. Bridging this implementation gap through earlier prevention, precision phenotyping, and integrated multidisciplinary care is essential to improving outcomes for HF patients @JanBiegus @K_smala @PMarkwirth @HFA_President @hfcollaboratory @GianluSava @GMCRosano @AmrAbdin10 @HSkouri academic.oup.com/eurjhf/advance…
Ahmed Bennis MD 🫀 tweet media
English
0
5
16
1K
Jan Biegus retweetledi
Martina Baiardo Redaelli
Martina Baiardo Redaelli@BaiardoMartina·
Interesting perspective @JAMA_current on sodium and decompensated 🫀failure. 🧂 Can Na+ supplementation facilitate decongestion in HF? No clear answer yet—but it’s a hypothesis worth challenging Take a few minutes to question your assumptions 💡 🔗 jamanetwork.com/journals/jamac…
Martina Baiardo Redaelli tweet media
English
0
3
8
257
Jan Biegus retweetledi
Ahmed Bennis MD 🫀
Ahmed Bennis MD 🫀@drbennisahmed·
💊 10 years post-PARADIGM-HF: Real-world data on Sacubitril/Valsartan in HFrEF tells a promising — but incomplete — story. ✅ 5-fold adoption increase by 2019 ✅ 4/5 patients adherent & persistent at 12 months ✅ ~2 years free from hospitalization vs conventional therapy Yet inadequate implementation is still limiting its full clinical benefit. Benefits are clear across the board: ↓ Reverse remodeling (NT-proBNP, EF, LVEDVI) ↓ Mitral regurgitation ↑ Quality of life & functional capacity ⚠️ Barriers remain: target dosing, hypotension, hyperkalemia Early adoption + consistent implementation = lives saved. #HFrEF #HeartFailure #Cardiology #Sacubitril #Valsartan #RealWorldEvidence
Ahmed Bennis MD 🫀 tweet media
English
0
9
20
1.1K
Jan Biegus retweetledi
Andrew J Sauer MD
Andrew J Sauer MD@AndrewJSauer·
Heart failure with mildly reduced and preserved ejection fraction remains one of the biggest areas of unmet need in cardiovascular medicine. In our recently published review (co-authored by @jozinetm and @GianluSava) in ESC Heart Failure, we examine the established and emerging pharmacologic options for HFmrEF and HFpEF, The larger message is clear: the therapeutic landscape is finally becoming more actionable, but treatment still needs to be more deliberate, phenotype-aware, and evidence-driven. A few key takeaways: SGLT2 inhibitors now have the strongest and most consistent evidence base across EF ≥40%. Finerenone has added important momentum as a promising option for HFmrEF/HFpEF, especially as we think more seriously about cardio-kidney-metabolic biology. Phenotype-specific treatment matters. Obesity, CKD, diabetes, atrial fibrillation, and other comorbidities are not side notes in HFpEF. They are central to the disease. The obesity-HFpEF space is evolving quickly, with incretins like semaglutide and tirzepatide helping push the field toward more targeted therapeutic strategies. And importantly, there is still substantial room for progress. Ongoing studies of newer approaches, including selective MR modulation and aldosterone synthase inhibition, may help address some of the major gaps that remain. HFpEF and HFmrEF are not therapeutic dead ends like they used to feel like just 5 years ago. But they do require us to think beyond a one-size-fits-all model. doi.org/10.1093/eschf/…
Andrew J Sauer MD tweet media
English
3
40
126
6.5K
Marcin Kurzyna
Marcin Kurzyna@marcin_kurzyna·
Top trending papers in Chronic Thromboembolic Pulmonary Hypertension - Poland as a country and European Health Center Otwock, as a single centre in distinguished companionship 😀 Chronic thromboembolic pulmonary hypertension: insights from the 100 most cited papers: a bibliometric perspective jtd.amegroups.org/article/view/1…
Marcin Kurzyna tweet mediaMarcin Kurzyna tweet mediaMarcin Kurzyna tweet media
English
2
1
11
225
Jan Biegus retweetledi
HFAPresident
HFAPresident@HFA_President·
Which drugs can worsen #HeartFailure? This #EJHF expert consensus highlights some pharmacologic pitfalls clinicians must recognize, for example: 📍NSAIDs: fluid retention
📍Antidiabetics (TZDs, some DPP4i): ⬆️risk of HF hospitalization
📍Non-DHP CCBs: negative inotropy
📍Antifungals (itraconazole, amphotericin B): myocardial toxicity, negative inotropy
📍Neuro/psych drugs (lithium, pramipexole): cause/exacerbate fluid overload
📍Some cancer treatments (e.g. Anthracyclines, HER2 targeted therapies: risk for cardiotoxicity 
Read more🔗 doi.org/10.1002/ejhf.7… @escardio @EJHFEiC @MarcoMetra @jozinetm @AmrAbdin10 @GianluSava #HFrEF
HFAPresident tweet mediaHFAPresident tweet mediaHFAPresident tweet mediaHFAPresident tweet media
English
1
71
205
9.9K

Keşfet

@ICardiacaSEC @IcyfaSemi @EJHFEiC @ppponikowski @hvanspall @ShelleyZieroth @FudimMarat @gcfmd